Unraveling IPF subtypes to guide prognosis and therapy
Official title: Unraveling idiopathic pulmonary fibrosis endophenotypes; a lung-centric approach to prognostic and therapeutic biomarker validation
Funded at University of Kansas Medical Center · NIH-11411171 · Data updated 2026-11-12
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | September 15, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $687,576 |
| NIH project number | 5R01HL176772-02 |
| Project ID | NIH-11411171 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with idiopathic pulmonary fibrosis who have available BALF and lung tissue samples and are or could be treated with current IPF therapies.
✕Less likely to help
Patients without IPF or those without available BALF/lung tissue samples for proteomic analysis may not benefit.
What this research studies
Researchers will analyze a large set of BALF and lung tissue samples from IPF patients around the world to find distinct protein patterns that track with survival and treatment response. They will look at autoinflammatory and immune signaling pathways to see if these endotypes predict who benefits from existing therapies. By validating these molecular clusters in a big patient cohort, the study seeks to move toward personalized management of IPF. The work builds on prior findings and uses advanced proteomics to connect biology with patient outcomes.
Why it matters
Potential benefit: If successful, patients with IPF could receive more personalized treatment plans based on their lung endotype, potentially improving survival and quality of life.
How similar studies have gone: Preliminary data in IPF endotypes suggest distinct prognostic protein patterns, with ongoing work aiming to validate these clusters in larger cohorts.
Where this research is happening
-
University of Kansas Medical Center
Kansas City, United States Active
Researchers
- Principal investigator: Matson, Scott Michael — University of Kansas Medical Center
- Study coordinator: Matson, Scott Michael
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
-
Adrenergic Nerves and Noradrenaline in Lung Fibrosis
A physician-scientist-in-training at Yale seeks to build a patient-focused research program on how nerve signals and adrenaline affect lung scarring in IPF.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.